project id: TCGA-PRAD; case submitter id: TCGA-EJ-AB20; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 0.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.25; rna integrity number: 7.0; age at index: 61; days to birth: -22626; ethnicity: not reported; gender: male; race: not reported; vital status: Alive; year of birth: 1952; age at diagnosis: 22626; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 131.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 136; initial weight: 180.0; sample id: 72735209-5da0-4ea3-9d81-a4f7200899b7; sample submitter id: TCGA-EJ-AB20-01A; portion id: 92c54224-6c8d-44ae-80a1-60571f17aa2d; portion submitter id: TCGA-EJ-AB20-01A-12; slide id: 44c864b0-d9e7-4a26-bc89-e705934847aa; slide submitter id: TCGA-EJ-AB20-01A-01-TS1; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 2.0; percent normal cells: 5.0; percent stromal cells: 25.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;